Authors:
Kristoferitsch, W
Seeldrayers, P
Kyriallis, K
Brochet, B
Confavreux, C
Clanet, M
Cesaro, P
Defer, G
Edan, G
Lyon-Caen, O
Pelletier, J
Rumbach, L
Roullet, E
Vermersch, P
Dengler, R
Zschenderlein, R
Storch-Hagenlocher, B
Sailer, M
Hohlfeld, R
Kunze, KP
Heesen, C
Bamborschke, P
Grunwald, F
Hartung, HP
Rieckmann, P
DeKeyser, J
Montalban, X
Fernandez, U
Arbizu, T
Sandberg, M
Kappos, L
Bates, D
Campbell, MJ
Capildeo, R
Compston, A
McLellan, DL
Wroe, S
Young, C
Clanet, M
Hartung, HP
Hohlfeld, R
Kappos, L
Radue, EW
Rieckmann, P
Sandberg, M
Polman, C
Kesselring, J
Thompson, A
Wekerle, H
Whitehead, J
Bains, H
Butler, E
Kooijmans-Coutinho, M
McAllister, A
Simonian, N
White, K
Anderson, D
Liddiard, S
Keane, R
Citation: W. Kristoferitsch et al., Double-blind randomized multicenter dose-comparison study of interferon-beta-1a (AVONEX): rationale, design and baseline data, MULT SCLER, 7(3), 2001, pp. 179-183
Authors:
Hutton, JT
Tolosa, ES
Capildeo, R
Morris, JL
Citation: Jt. Hutton et al., Levodopa-treated Parkinsons disease has better long-term outcome than previously predicted, ARCH NEUROL, 57(5), 2000, pp. 758-759
Authors:
Tubridy, N
Behan, PO
Capildeo, R
Chaudhuri, A
Forbes, R
Hawkins, CP
Hughes, RAC
Palace, J
Sharrack, B
Swingler, R
Young, C
Moseley, IF
MacManus, DG
Donoghue, S
Miller, DH
Citation: N. Tubridy et al., The effect of anti-alpha 4 integrin antibody on brain lesion activity in MS, NEUROLOGY, 53(3), 1999, pp. 466-472